Retraction Notice: The Role of MicroRNA-935 in Targeting FZD6

Overview

This report details the retraction of the original research article regarding microRNA-935's role in glioblastoma. The retraction was due to concerns about the integrity of the images in the published figures.

Background

Remove unsupported claims about the need for reliable research and data integrity.

Data Highlights

No numerical or trial data is presented in the retraction notice.

Key Findings

• The original article was retracted due to concerns about image integrity.
• The authors did not provide a satisfactory explanation during the investigation.
• The retraction was approved by the Chief Editors of Frontiers in Oncology.
• Concerns were raised by users on PubPeer regarding the validity of the data.
• The retraction was formally communicated to the authors, who had the opportunity to respond.

Clinical Implications

The retraction emphasizes the importance of data integrity in glioblastoma research. Clinicians and researchers should critically evaluate published studies, especially those that may influence treatment approaches.

Conclusion

The retraction of this article serves as a reminder of the necessity for rigorous standards in scientific publishing, particularly in high-stakes fields like oncology.

Related Resources & Content

1. Frontiers Editorial Office, Frontiers in Oncology, 2026 -- Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis
2. Journal of Neuro-Oncology (Springer) — Retraction Note: Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway
3. Journal of Neuro-Oncology — The Role of MicroRNA-1231 as a Tumor Suppressor in Regulating the EGFR/PI3K/AKT Pathway in Glioma
4. The ASCO Post — Effect of Micro-RNA on M2 Macrophages and Murine Glioblastoma
5. Frontiers in Immunology — MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances
6. cIMPACT‐NOW update 11: Proposal on adaptation of diagnostic criteria for IDH‐ and H3‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors - PMC
7. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma - PubMed
8. EANO/ESTRO Reirradiation of Glioblastoma Guideline Summary - Guideline Central